News | April 06, 2026
Red Nucleus acquires Bridge Medical Consulting with advisory support from VERTICES PARTNERS
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
The record-setting effort stems from Danone India’s nationwide ‘IRON UP!’ campaign
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Subscribe To Our Newsletter & Stay Updated
